AI spillovers are reshaping biotech investment as tech-bio gains momentum

AI could accelerate biotechnology and encourage traditional technology investors to write more checks into biotech companies, although it remains unclear how quickly a new investment wave will emerge.

In this context, “crossover” refers to hedge funds and mutual funds from public markets making private placements in biotech companies going through FDA approval and potentially preparing for an IPO—not software venture capital moving into biotech. At later stages, such investors could act aggressively, seek favorable structures and support earlier, more aggressive public listings.

New fund formation in pure biotech has not matched that of other technology categories. Dedicated tech-bio specialists from the technology sector are emerging, while a strong tech-bio syndicate is viewed as combining traditional biotech managers with technology-focused groups. Tech-bio will probably grow at a much faster pace than pure biotech over the next three to five years.